StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a research report released on Monday morning. The firm issued a sell rating on the medical research company’s stock.
OpGen Stock Up 3.0 %
Shares of OPGN opened at $2.37 on Monday. OpGen has a fifty-two week low of $1.65 and a fifty-two week high of $38.40. The firm’s 50 day moving average price is $2.74 and its 200 day moving average price is $4.13.
OpGen (NASDAQ:OPGN – Get Free Report) last issued its earnings results on Monday, July 8th. The medical research company reported $0.21 earnings per share (EPS) for the quarter. OpGen had a negative net margin of 997.34% and a negative return on equity of 1,827.76%. The business had revenue of $0.17 million during the quarter.
Hedge Funds Weigh In On OpGen
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
See Also
- Five stocks we like better than OpGen
- What Do S&P 500 Stocks Tell Investors About the Market?
- Owens-Corning Stock: Good Value or Recession Red Flag?
- How to Calculate Inflation Rate
- Datadog Exceeds Q2 Expectations, Solidifies Market Leadership
- How to Use the MarketBeat Excel Dividend Calculator
- Cybersecurity Stock Surges, Promising Double-Digit Gains
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.